EORTC Prepares to Show How to Navigate Regulatory Triangle
How can you navigate the regulatory triangle safely?
How can you navigate the regulatory triangle safely? Who better to address this question than the respected Brussels-based European Organization for Research and Treatment of Cancer (EORTC).
For anybody seeking regulatory tips and tricks on clinical trials, in vitro diagnostics and data protection, EORTC is staging a workshop in Brussels on 2 December. During the same week, it is organizing two-day meetings about innovation and biomarkers in cancer drug development and markers in cancer diagnostic development.
Among its partners in these events are the European Medicines Agency, the National Cancer Institute, the American Association for Cancer Research, and the American Society of Clinical Oncology.
The EORTC is an independent research organization dedicated to investigator driven clinical trials and translational research. Consisting of both a network and a coordinating scientific and operational infrastructure, it seeks to not only establish ‘state-of-the-art’ treatments but also ensure that new cancer agents are developed and tested efficiently with the aim of minimizing delays between laboratory discovery and their therapeutic benefit for patients.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
